ChengDa Pharmaceuticals Valuation

Q: What is the Fair Price of 301201 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

301201 (CN¥21.8) is trading above our estimate of [[fair value]] (CN¥4.83)

Is 301201 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301201 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301201 (CN¥21.8) is trading above our estimate of fair value (CN¥4.83)

Significantly Below Fair Value: 301201 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301201?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 301201. This is calculated by dividing 301201's market cap by their current preferred multiple.
What is 301201's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥3.30b

301201 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5x
Enterprise Value/EBITDA	25.8x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 301201's PE Ratio compare to its peers?

The above table shows the PE ratio for 301201 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	74x
688073 Bide Pharmatech	42.6x	27.5%	CN¥3.3b
002198 Guangdong Jiaying Pharmaceutical	160.4x	n/a	CN¥3.5b
600613 Shanghai Shenqi Pharmaceutical Investment Management	56.2x	n/a	CN¥3.3b
000788 PKU HealthCareLtd	37x	n/a	CN¥3.7b
301201 ChengDa Pharmaceuticals	38.1x	n/a	CN¥3.3b

Price-To-Earnings vs Peers: 301201 is good value based on its Price-To-Earnings Ratio (38.1x) compared to the peer average (74x).

Price to Earnings Ratio vs Industry

How does 301201's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.6%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	18.6%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 301201 is expensive based on its Price-To-Earnings Ratio (38.1x) compared to the CN Pharmaceuticals industry average (29.7x).

Price to Earnings Ratio vs Fair Ratio

What is 301201's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301201 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	38.1x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 301201's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.